Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7018-7024

  Marzac, Christophe ^a,b   Teyssandier, I ^b   Calendini, Ors'Anton ^b   Perrot, Jean Yves ^b   Faussat, Anne Marie ^a   Tang, Ruoping ^a   Casadevall, Nicole ^b   Marie, Jean Pierre ^a,b   Legrand, Ollivier ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-GLYCOPROTEINS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 33845732217     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0641     Document Type: Article

References (50)

1. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 1999;13:1481-90.
2. Avivi I, Rowe JM. Prognostic factors in acute myeloid leukemia. Curr Opin Hematol 2005;12:62-7.
3. Leith C, Kopecky K, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. Blood 1997;89:3323-9.
4. Legrand O, Simonin G, Beauchamp-Nicoud A, et al. Simultaneous activity of MRF1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999;94:1046-56.
5. Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896-902.
6. Benderra Z, Faussat AM, Sayada L, et al. MRP3, BCRP, P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11:7764-72.
7. Mrozek K, Heeremab NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-36.
8. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
9. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-83.
10. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
11. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
12. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-75.
13. Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia: analysis of 848 patients. Leukemia 2001;15:903-9.
14. Marcucci G, Mrozek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005;12:68-75.
15. Preudhomme C, Sagot C, Boissel N, et al. Prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-23.
16. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33.
17. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A 2001;98:13901-6.
18. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001;113:983-8.
19. Illmer T, Thiede C, Fredersdorf A, et al. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res 2005;11:3217-24.
20. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
21. Profiling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80.
22. Abu-Duhier F, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in acute myeloid leukaemia (AML) define a poor risk group. Br J Haematol 2001;111:190-5.
23. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
24. Zheng R, Friedman AD, Levis M, et al. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPa expression. Blood 2004;103:1883-90.
25. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001;61:7233-9.
26. Legrand O, Zompi S, Perrot JY, et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetic risk groups. Haematologica 2004;89:34-41.
27. Abu-Duhier F, Goodeve AC, Wilson GA, et al. Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol 2001;113:1076-89.
28. Legrand O, Perrot JY, Simonin G, et al. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 2001;97:502-8.
29. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
30. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
31. Marie JP, Brophy NA, Ehsan MN, et al. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 1992;81:145-52.
32. Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood 2003;102:2198-204.
33. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 2003;37:237-51.
34. Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPa in t(8;21) myeloid leukemia. Nat Med 2001;7:444-51.
35. Schaich M, Soucek S, Thiede C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2004;128:324-32.
36. Hunter HM, Pallis M, Seedhouse CH, et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol 2004;127:26-33.
37. Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003;102:1202-10.
38. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32.
39. Gerrard G, Payne E, Baker RJ, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004;89:782-90.
40. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20.
41. Stone MR, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
42. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
43. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76.
44. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885-91.
45. Bullinger L, Döhner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-16.
46. Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-24.
47. Oppliger Leibundgut E, Bienz M, Ludwig M, et al. CEBPA mutations, FLT3/ITD and BAALC expression define distinct prognostic subsets in normal karyotype acute myeloid leukemia (AML). Hematol J 2004;5:S148.
48. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
49. Erratum in: N Engl J Med 2005;352:740.
50. Fröhling S, Richard F, Schlenk RF, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;5:109-16.